Invention Grant
US08552034B2 Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
有权
3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2-基）苯甲酸的药物组合物，
![Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof](/docs/US/2013-10-08/US08552034B2/abs.jpg.600x600.jpg)
- Patent Title: Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
- Patent Title (中): 3-（6-（1-（2,2-二氟苯并[d] [1,3]二氧杂环戊烯-5-基）环丙烷甲酰氨基）-3-甲基吡啶-2-基）苯甲酸的药物组合物，
-
Application No.: US13081750Application Date: 2011-04-07
-
Publication No.: US08552034B2Publication Date: 2013-10-08
- Inventor: Marinus Jacobus Verwijs , Rossitza Gueorguieva Alargova , Ritu Rohit Kaushik , Irina Nikolaevna Kadiyala , Christopher Young
- Applicant: Marinus Jacobus Verwijs , Rossitza Gueorguieva Alargova , Ritu Rohit Kaushik , Irina Nikolaevna Kadiyala , Christopher Young
- Applicant Address: US MA Cambridge
- Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee: Vertex Pharmaceuticals Incorporated
- Current Assignee Address: US MA Cambridge
- Agent Michael J. DiVerdi
- Main IPC: A61K31/443
- IPC: A61K31/443 ; C07D405/12
![Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof](/abs-image/US/2013/10/08/US08552034B2/abs.jpg.150x150.jpg)
Abstract:
A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.
Public/Granted literature
Information query
IPC分类:
